Scleroza multiplă și viața cu aceasta.
71 de articoleA study of 287 MS brain tissue samples from the Netherlands Brain Bank identifies specific pathological features, including broad rim lesions and myelin repair failures, that explain variability in disease progression. Individual genetic backgrounds modulate these pathological processes, offering insights into why MS progresses differently among patients.
Researchers identified distinct biological patterns in MS patients' brains that correlate with disease progression rates and severity. These patterns have a genetic component, potentially explaining why some individuals experience rapid disease advancement while others remain stable over extended periods.
Researchers identified that immune cells laden with fat droplets from damaged myelin accumulate in severe MS brain tissue and may shift from a reparative to a pro-inflammatory state. This finding offers insights into why MS progression varies between patients and could inform new therapeutic approaches.
This study investigates circulating proteins and microRNAs in cerebrospinal fluid and serum as potential biomarkers to differentiate MS disease subtypes and guide treatment decisions. Analysis of two cohorts identified 13 cerebrospinal fluid proteins and 10 serum proteins that differed between MS patients and controls, with 16 serum microRNAs distinguishing between relapsing-remitting and secondary progressive MS.
This systematic scoping review identified 11 studies examining frailty in people with multiple sclerosis, finding frailty prevalence ranges from 17–66% with early onset compared to the general population. Higher disability levels, longer disease duration, and progressive MS subtypes were consistently associated with frailty, which also correlated with reduced walking performance, poor sleep quality, fatigue, and lower quality of life.
Research presented at the European Academy of Neurology Congress 2026 demonstrates that MS substantially affects non-physical aspects of life, with over half of patients reporting impacts on social functioning and nearly half reporting work-related consequences. The study highlights the importance of addressing psychosocial dimensions alongside physical symptoms in MS management.
